(Q39194082)

9 September 2017

title

Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy (English)

1 reference

9 September 2017

1 reference

Koji Teramoto

1

1 reference

9 September 2017

Yasuhiko Ohshio

2

1 reference

9 September 2017

Takuya Fujita

3

1 reference

9 September 2017

Jun Hanaoka

4

1 reference

9 September 2017

Keiichi Kontani

5

1 reference

9 September 2017

publication date

15 February 2013

1 reference

Journal of Cancer Research and Clinical Oncology

9 September 2017

published in

1 reference

9 September 2017

volume

139

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

861-870

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-013-1394-4

9 September 2017

exact match

0 references

cites work

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-Ab molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Dendritic cell vaccines in melanoma: from promise to proof?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1394-4

Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein

21 January 2018

1 reference

12 December 2020

Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.

1 reference

12 December 2020

Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers

1 reference

12 December 2020

Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas

1 reference

12 December 2020

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

1 reference

12 December 2020

Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma

1 reference

12 December 2020

The role of CD4+ T cell responses in antitumor immunity

1 reference

12 December 2020

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

1 reference

12 December 2020

Determination of amino acids on agretopes of pigeon cytochrome c-related peptides specifically bound to I-A allelic products

1 reference

12 December 2020

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

12 December 2020

Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.

1 reference

12 December 2020

Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody

1 reference

12 December 2020

10.1007/S00432-013-1394-4

Identifiers

DOI

1 reference

9 September 2017

1 reference